University of Pittsburgh Clinical and Translational Science Institute
Document text
Principal Investigator: STEVEN E REIS Organization: UNIVERSITY OF PITTSBURGH AT PITTSBURGH Fiscal Year: 2020 Award: $842,907 Funding agency: National Center for Advancing Translational Sciences ABSTRACT The pandemic caused by the SARS-CoV-2 virus continues to impact public health and the health of individuals, families, and communities. Those with a rare disease may be disproportionately affected because they may have a high risk of exposure to SARS-CoV-2 from their caregivers, housing situations, and need to attend in- person medical appointments. They may also be particularly vulnerable to complications from infection due to their underlying disease condition, immunosuppressive therapies, genetic susceptibility, and/or other factors. The scope of infection among those with rare diseases is unknown. The present proposal will investigate the sero-prevalence of immunity against SARS-CoV-2 among asymptomatic individuals with rare diseases. Specifically, this study will determine the prevalence of detectable antibodies to SARS-CoV-2 (Aim 1) and investigate the immune attributes associated with health outcomes across the life course (Aim 2) among asymptomatic individuals across the United States with one of >280 rare diseases. The anticipated results will provide crucial insights into the magnitude of the COVID-19 pandemic in the context of rare disease and will contribute to the identification of potential targets for a vaccine. Terms: <19S Gamma Globulin><2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><Academic Medical Centers><Access to Care><Affect><Anti-Rejection Therapy><Antibodies><Antibody titer measurement><Antirejection Therapy><Assay><Bioassay><Biologic Assays><Biological Assay><Biological Markers><Blood Sample><Blood specimen><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Care Givers><Caregivers><Clinical Research><Clinical Sciences><Clinical Study><Communities><Development><Diagnosis><Disease><Disorder><ELISA><Economics><Emotional><Enzyme-Linked Immunosorbent Assay><Exposure to><Family><Family Care Giver><Family Caregiver><Future><General Population><General Public><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Susceptibility><Goals><Health><Health Services Accessibility><Herd Immunity><Housing><Humoral Immunities><IgG><IgM><Immune><Immunes><Immunity><Immunoglobulin G><Immunoglobulin M><Immunosuppressive Therapy><Individual><Infection><Inherited Predisposition><Inherited Susceptibility><Institutes><Intramural Program><Intramural Research Program><Knowledge><Life Cycle><Life Cycle Stages><Measures><Morbidity><Morbidity - disease rate><NIAID><NIBIB><NIH><National Institute of Allergy and Infectious Disease><National Institute of Biomedical Imaging and Bioengineering><National Institutes of Health><Orphan Disease><Outcome><Participant><Persons><Population><Prevalence><Proteins><Public Health><Rare Diseases><Rare Disorder><Reporting><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Seroprevalences><Severe acute respiratory syndrome coronavirus 2><Survey Instrument><Surveys><Symptoms><Therapeutic immunosuppression><Translational Research><Translational Science><United States><United States National Institutes of Health><Universities><University Medical Centers><Vaccines><Viral><Virus><Wuhan coronavirus><access to health services><access to services><access to treatment><accessibility to health services><antibody titering><antibody-based immunity><artificial immunosuppression><availability of services><bio-markers><biologic marker><biomarker><care access><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><developmental><genetic etiology><genetic mechanism of disease><genetic vulnerability><genetically predisposed><health service access><health services availability><high risk><immunosuppression therapy><insight><life course><medical appointment><medical supply><mortality><novel><orphan disorder><pandemic><pandemic disease><research study><response><screening><service availability><translation research><treatment access>